Advisory Team

Dr. J. Galvin

James E. Galvin, MD, MPH is the Professor of Neurology and Psychiatry & Behavioral Sciences at the University of Miami Miller School of Medicine.

He is Alexandria & Bernard Schoninger Endowed Chair in Memory Disorders, Founding Director of the Comprehensive Center for Brain Health, Director and Principal Investigator of the Lewy Body Dementia Research Center of Excellence, and Chief of Division of Cognitive Neurology for Palm Beach and Broward County leading their brain health and neurodegenerative disease research and clinical programs.


Dr. L. Natbony

Lauren R. Natbony, MD, FAHS, is the Founder & Medical Director of Integrative Headache Medicine of New York. She is also an Assistant Clinical Professor of Neurology in the Division of Headache and Facial Pain at Mount Sinai’s Icahn School of Medicine. Dr. Natbony previously served as the Director of the Headache Medicine Fellowship at Mount Sinai and continues to be actively involved in teaching headache fellows and neurology residents. She is board-certified in Neurology by the American Board of Psychiatry and Neurology and in Headache Medicine by the United Council of Neurologic Subspecialties.

Dr. Natbony is also a leader in the field of Headache Medicine, reflected in her designation as a Fellow of the American Headache Society (FAHS). She also serves as the Secretary General of the World Headache Society.


Dr. M. Madsen

Dr. Martin Madsen, a Danish physician and neurobiology researcher in Copenhagen, boasts a diverse career. Before joining Herlev Hospital, he combined medical practice with research, earning his PhD at the Neurobiology Research Unit (NRU) at Rigshospitalet. In 2012, he received the Danish Regions’ Prize Award in Psychiatry and has been teaching neurology and internal medicine at Professionshøjskolen Metropol (Metropol College) since 2014.
Dr. Madsen’s research centers on the impact of serotonin 5-HT2A receptor modulation on brain function and structure, utilizing advanced neuroimaging methods like PET scans and fMRI. In 2019, he led a study confirming the link between psilocin binding to 5-HT2A and psychedelic experiences. Subsequent research explored the long-term effects of psilocybin, revealing a connection to increased mindfulness and subtle changes in 5-HT2A receptor levels. A 2020 publication further clarified the relationship between psilocin levels in plasma and psilocybin’s effects, and a study he contributed to in 2020 highlighted individual differences in pre-drug 5-HT2A binding and their impact on the psilocybin experience.